Clinical trial

A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine…

NCT00427453 · University of Oxford, Other · Completed

Key facts

NCT number NCT00427453
Title A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month Previously
Official title A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month Previously
Lead sponsor University of Oxford, Other
Status Completed
Phase Phase 1
Study type Interventional
Conditions Tuberculosis
Intervention type Biological
Interventions MVA85A
Enrollment 12
Start date Jun 1, 2003
Completion Mar 1, 2005
First posted Jan 29, 2007
Last update posted Jan 29, 2007
Countries United Kingdom

At a glance

  • 1–9 Study sites
  • No Results posted
  • 1–9 Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies